<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Crohns Colitis 360</journal-id><journal-id journal-id-type="iso-abbrev">Crohns Colitis 360</journal-id><journal-id journal-id-type="publisher-id">crohnscolitis360</journal-id><journal-title-group><journal-title>Crohn's &#x00026; Colitis 360</journal-title></journal-title-group><issn pub-type="epub">2631-827X</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38028952</article-id><article-id pub-id-type="pmc">PMC10668916</article-id><article-id pub-id-type="doi">10.1093/crocol/otad071</article-id><article-id pub-id-type="publisher-id">otad071</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00260</subject><subject>AcademicSubjects/MED00760</subject><subject>AcademicSubjects/MED00972</subject></subj-group></article-categories><title-group><article-title>Correction to: Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn&#x02019;s Disease: Post Hoc Analyses of VISIBLE Studies</article-title></title-group><pub-date pub-type="collection"><month>10</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-11-24"><day>24</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>11</month><year>2023</year></pub-date><volume>5</volume><issue>4</issue><elocation-id>otad071</elocation-id><history><date date-type="corrected-typeset"><day>24</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's &#x00026; Colitis Foundation.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="otad071.pdf"/><related-article related-article-type="corrected-article" ext-link-type="doi" id="u1" xlink:href="10.1093/crocol/otad034"/><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Takeda Pharmaceuticals U.S.A.</institution><institution-id institution-id-type="DOI">10.13039/100007723</institution-id></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="1"/></counts></article-meta></front><body><p>This is a correction to: William J Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V Loftus, Geert D&#x02019;Haens, Ninfa Candela, Karen Lasch, Douglas C Wolf, Sharif M Uddin, Silvio Danese, Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn&#x02019;s Disease: Post Hoc Analyses of VISIBLE Studies, <italic toggle="yes">Crohn&#x02019;s &#x00026; Colitis 360</italic>, Volume 5, Issue 3, July 2023, otad034, <ext-link xlink:href="https://doi.org/10.1093/crocol/otad034" ext-link-type="uri">https://doi.org/10.1093/crocol/otad034</ext-link></p><p>In the originally published version of this manuscript there was an error in the definition of clinical remission in the second paragraph underneath the heading &#x0201c;Evaluation of Clinical Remission and Response&#x0201d;. The sentence incorrect read:</p><p>&#x0201c;Clinical remission was defined as a partial Mayo score of &#x02265;2 and no individual subscore of &#x0003e;1 for patients with UC, or an HBI score of &#x02264;4 for patients with CD.&#x0201d;</p><p>This has now been corrected to:</p><p>&#x0201c;Clinical remission was defined as a partial Mayo score of &#x02264;2 and no individual subscore of &#x0003e;1 for patients with UC, or an HBI score of &#x02264;4 for patients with CD.&#x0201d;</p><p>This error has been corrected.</p></body></article>
